Latest Precigen News & Updates

See the latest news and media coverage for Precigen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Precigen

Gene and cell therapy biopharmaceutical company

precigen.com

Headquarters: Germantown, United States
Founded year: 2020
Company type: Public company
Number of employees: 150–200

Last updated Today

Latest news about Precigen

In short: Precigen achieved a historic milestone with the FDA approval and successful commercial launch of PAPZIMEOS for recurrent respiratory papillomatosis.

Company announcements

May 30 Precigen

Precigen presents new long-term durability data for PAPZIMEOS

83% of complete responders maintained response for at least 36 months, with five beyond four years, and the drug received seven-year market exclusivity.

May 27 Precigen

Precigen will present pivotal trial data at symposium

The data shows complete responses and reduced surgical debulking in recurrent respiratory papillomatosis patients.

May 27 Precigen

Precigen receives orphan drug exclusivity for PAPZIMEOS

The FDA granted seven-year market exclusivity for the RRP treatment, effective through August 2032.

May 13 Precigen

Precigen reports Q1 2026 financial results and updates

PAPZIMEOS generated $21.6M in net product revenue, with 400 patients enrolled and strong payer coverage.

Media coverage

June 15 Yahoo Finance

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Meg Flippin, Benzinga Staff Writer Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference ...

May 31 Yahoo Finance

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced updated...

May 27 Morningstar

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene...

Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced ...

May 21 Newser

Precigen (PGEN) Posts Q1 2026 Earnings Beat — Here's What Drove It

Portfolio recommendations, risk assessment tools, and market forecasts. Join thousands who trust our analysis. During the first-quarter earnings call, management highlighted progress in advancing ...

Never miss news about Precigen

Track Precigen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Precigen competitors & trending companies

Browse news for competitors to Precigen and other trending companies.